Our Vital Microbiome
The infinite potential of the human microbiome is only now becoming clearer. Evidence is growing on the influence of bacteria on areas such as brain health, obesity and management of viral infections.
However, modern lifestyles can mean that many are born with a restricted microbiome or go on to develop one.
PrecisionBiotics (PB) and its partners have been key to driving recognition of the vital role that specific strains have on human health. There is now growing acceptance by healthcare professionals of the microbiome’s importance, accelerated by the increase in high quality clinical evidence. There is also greater awareness of the role of individual strains and their unique properties.
Our 35624® strain is now a standard of care for IBS patients as the Number 1 recommended probiotic by US Gastroenterologists and Doctors*.
Our 1714-Serenitas® strain is amongst the first to validate the potential of the gut-brain axis.
Our Approach to R&D: Precision and Evidence
We provide probiotics for targeted indications, supported by clinical evidence.
The trillions of unique microbes (microbiota) and their genes (microbiome) that reside within the human body provide incredible potential for improving human health. We are recognised for our expertise in identifying, characterising and selecting precise probiotic strains have a significant and measurable impact on human health.
This expertise has enabled us to discover ground-breaking strains such as the 35624® and 1714® strains, both Bifidobacterium longum strains, as well as an extensive portfolio of human origin strains currently in development.
Building on our expertise in discovery and characterisation, we confirm precision activity by validating each strain through a human clinical trial program.
PrecisionBiotics Precise approach
We have published in top tier journals and have over 100 peer-reviewed publications to date.
American Journal of Gastroenterology
New England Journal of Medicine
Reviews in Gastroenterological Disorders
Journal of American Dietetic Association
American Journal of Physiology Gastrointestinal and Liver Physiology
American Family Physicial
Applied and Environmental Microbiology
Clinical and Experimental Immunology
Current issues in Intestinal Microbiology
Current Pharmaceutical Design
Journal of Clinical Gastroenterology
Journal of Psychiatric ResearchJournal of Translational Psychiatry
Strategic partnerships with Research Leaders
We also partner with global leaders in microbiome research. We are a founding partner of APC Microbiome Ireland, a world renowned centre of expertise in the interaction of the microbiome with disciplines such as microbiology, immunology, gastroenterology, psychiatry, pharmacology, neuroscience, food science, nutrition, biochemistry, medical microbiology, pharmacy, radiology and pathology.
We offer partners our expertise in microbiome research and development and contribute in-depth competence in areas such as product development, product scale-up and regulatory support.
Over the last 2 decades, PrecisionBiotics has generated an extensive portfolio of human origin strains.
Our unique portfolio of human strains is available to our partners, along with our considerable know-how for screening and selecting bacterial strain candidates for specific health issues.
PrecisionBiotics’ R&D activities are focused on the use of bacteria and their components in key areas such as inflammation, infection and brain-gut interaction.
We are applying this to innovative products and ingredients in disease areas such as:
Gastrointestinal Health: PB continues to build and support its position in gut health and further advance our science in IBS and related conditions.
Stress & Sleep: with recent advances and interest in the gut-brain axis, supported by our discovery of the 1714-Serenitas® strain, PB is focused on the development of further evidenced based probiotics for the management of stress, stress-related fatigue, cognition and learning.
Metabolic health: PB is investigating applications of bacterial strains in metabolic conditions and liver health, including fatty liver disease.
We are also developing unique products targeting key life stages, including
Pregnancy & early Life: building on new research about the importance of appropriate microbiome seeding of new born babies and the impact on later life, we are studying interventions with well characterised strains for mum and baby to set a child's future health on the right path.
Healthy Aging: knowledge is growing on the role of inflammation in aging and of the gut-brain axis on cognition. AH is researching the impact that selected strains have on these key processes.
*Among gastroenterologists who recommended a brand of probiotic in AlphaImpactRx 2008–2017 surveys. Among doctors who recommended a brand of probiotic in AlphaImpactRx 2017 survey.